Bristol/ImClone Erbitux BLA Resubmission Expected During First Quarter
Executive Summary
ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment